Literature DB >> 26670151

[Long Bone Nonunion].

G Schmidmaier1, A Moghaddam1.   

Abstract

The percentage of delayed or non-unions after fractures of long bones depends on the individual risk profile at approximately 10 %. The current definition states that a non-union is a fracture that will not consolidate without any further intervention - independent from the treatment time. At the early stage of a non-union a conservative treatment is possible in case of an adequately stable situation. The operative treatment depends on the type of the non-union. There are one-step or two-step procedures, all according to the principles of the "diamond concept". This means improvement of the mechanical situation - in most cases by means of a reosteosynthesis - and vascularization, local application of osteoconductive carriers e.g. tricalciumphosphate, vital cells from autologous bone and osteoinductive substances like bone morphogenetic proteins (BMP-2 or BMP-7). Hypertrophic and atrophic non-unions without large defect gaps or signs of infection can be treated with a one-step procedure. For treating infected non-unions or non-unions with large defect gaps the Masquelet technique is recommended. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26670151     DOI: 10.1055/s-0035-1558259

Source DB:  PubMed          Journal:  Z Orthop Unfall        ISSN: 1864-6697            Impact factor:   0.923


  19 in total

1.  Low intensity pulsed ultrasound in the treatment of long bone nonunions: Evaluation of cytokine expression as a tool for objectifying nonunion therapy.

Authors:  Arash Moghaddam; Timur Mert Yildirim; Fabian Westhauser; Wolfgang Danner; Tyler Swing; Thomas Bruckner; Bahram Biglari
Journal:  J Orthop       Date:  2016-07-02

2.  [Tibial defects and infected non-unions : Treatment results after Masquelet technique].

Authors:  A Moghaddam; C Ermisch; C Fischer; S Zietzschmann; G Schmidmaier
Journal:  Orthopade       Date:  2017-03       Impact factor: 1.087

3.  Bone formation of human mesenchymal stem cells harvested from reaming debris is stimulated by low-dose bone morphogenetic protein-7 application in vivo.

Authors:  Fabian Westhauser; Melanie Höllig; Bruno Reible; Kai Xiao; Gerhard Schmidmaier; Arash Moghaddam
Journal:  J Orthop       Date:  2016-08-29

4.  The Influence of an Occult Infection on the Outcome of Autologous Bone Grafting During Surgical Bone Reconstruction: A Large Single-Center Case-Control Study.

Authors:  Michael C Tanner; Raban Arved Heller; Andreas Grimm; Stefan Zimmermann; Maximilian Pilz; Louisa Jurytko; Matthias Miska; Lars Helbig; Gerhard Schmidmaier; Patrick Haubruck
Journal:  J Inflamm Res       Date:  2021-03-22

5.  The treatment of nonunions with application of BMP-7 increases the expression pattern for angiogenic and inflammable cytokines: a matched pair analysis.

Authors:  Patrick Haubruck; Andreas Kammerer; Sebastian Korff; Philipp Apitz; Kai Xiao; Axel Büchler; Bahram Biglari; Gerald Zimmermann; Volker Daniel; Gerhard Schmidmaier; Arash Moghaddam
Journal:  J Inflamm Res       Date:  2016-09-22

6.  Long-term outcome following additional rhBMP-7 application in revision surgery of aseptic humeral, femoral, and tibial shaft nonunion.

Authors:  Simon Hackl; Christian Hierholzer; Jan Friederichs; Alexander Woltmann; Volker Bühren; Christian von Rüden
Journal:  BMC Musculoskelet Disord       Date:  2017-08-07       Impact factor: 2.362

7.  Evaluation of the clinical effectiveness of bioactive glass (S53P4) in the treatment of non-unions of the tibia and femur: study protocol of a randomized controlled non-inferiority trial.

Authors:  Michael C Tanner; Raban Heller; Fabian Westhauser; Matthias Miska; Thomas Ferbert; Christian Fischer; Simone Gantz; Gerhard Schmidmaier; Patrick Haubruck
Journal:  Trials       Date:  2018-05-30       Impact factor: 2.279

8.  Non-unions treated with bone morphogenic protein 7: introducing the quantitative measurement of human serum cytokine levels as promising tool in evaluation of adjunct non-union therapy.

Authors:  Arash Moghaddam; Lisa Breier; Patrick Haubruck; Daniel Bender; Bahram Biglari; Andreas Wentzensen; Gerald Zimmermann
Journal:  J Inflamm (Lond)       Date:  2016-01-22       Impact factor: 4.981

9.  Treatment with recombinant human bone morphogenetic protein 7 leads to a transient induction of neutralizing autoantibodies in a subset of patients.

Authors:  Andrea Schuette; Arash Moghaddam; Petra Seemann; Georg N Duda; Gerhard Schmidmaier; Lutz Schomburg
Journal:  BBA Clin       Date:  2016-08-03

10.  Patients' safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?

Authors:  Arash Moghaddam; Viola Graeser; Fabian Westhauser; Ulrike Dapunt; Till Kamradt; Stefan M Woerner; Gerhard Schmidmaier
Journal:  Ther Clin Risk Manag       Date:  2016-09-07       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.